for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ADMA Biologics Inc

ADMA.OQ

Latest Trade

3.96USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.08

 - 

6.31

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.96
Open
--
Volume
--
3M AVG Volume
15.99
Today's High
--
Today's Low
--
52 Week High
6.31
52 Week Low
2.08
Shares Out (MIL)
59.32
Market Cap (MIL)
234.60
Forward P/E
-3.90
Dividend (Yield %)
--

Latest Developments

More

Adma Biologics Files For Mixed Shelf Of Upto $200 Mln - SEC Filing

ADMA Biologics Q2 Loss Per Share $0.25

Adma Biologics Receives FDA Approval For License Transfers For Bivigam And Nabi-Hb

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ADMA Biologics Inc

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Industry

Biotechnology & Drugs

Contact Info

C/O Adma Biologics

Inc., 465 State Route 17

+1.201.4785552

https://www.admabiologics.com/

Executive Leadership

Steven A. Elms

Chairman of the Board

Adam S. Grossman

President, Chief Executive Officer, Co-Founder, Director

Jerrold B. Grossman

Vice Chairman of the Board, Co-Founder

Brian Lenz

Chief Financial Officer, Executive Vice President

James Mond

Chief Scientific and Medical Officer

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.610

2017

-1.650

2018

-1.450

2019(E)

-1.013
Price To Earnings (TTM)
--
Price To Sales (TTM)
12.77
Price To Book (MRQ)
5.00
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
179.08
LT Debt To Equity (MRQ)
178.60
Return on Investment (TTM)
-48.74
Return on Equity (TTM)
-45.55

Latest News

Latest News

UPDATE 1-FDA declines to approve re-launch of ADMA Biologics' Bivigam

The U.S. Food and Drug Administration (FDA)on Wednesday declined to approve ADMA Biologics Inc's application to re-launch its immune deficiency treatment Bivigam, the company said.

FDA declines to approve re-launch of ADMA Biologics' Bivigam

The U.S. Food and Drug Administration on Wednesday declined to approve ADMA Biologics Inc's application to re-launch its immune deficiency treatment Bivigam, the company said.

BRIEF-ADMA Biologics Files For Mixed Shelf Offering Of Up To $100 Mln

* ADMA BIOLOGICS FILES FOR MIXED SHELF OFFERING OF UP TO $100 MILLION - SEC FILING Source http://bit.ly/2IrSugh Further company coverage:

BRIEF-ADMA Biologics Retires About 8.6 Million Shares Previously Issued to Biotest

* ADMA BIOLOGICS INC - RETIRES APPROXIMATELY 8.6 MILLION SHARES PREVIOUSLY ISSUED TO BIOTEST PHARMACEUTICALS CORPORATION AND ITS FORMER PARENT, BIOTEST AG

BRIEF-ADMA Biologics Releases Its First Commercial Batch Of Nabi-HB Manufactured Under Its Ownership

* ADMA BIOLOGICS ANNOUNCES THE RELEASE OF ITS FIRST COMMERCIAL BATCH OF NABI-HB MANUFACTURED UNDER ITS OWNERSHIP

BRIEF-ADMA Files Biologics License Application For Its Third Plasma Collection Center

* ADMA FILES BIOLOGICS LICENSE APPLICATION FOR ITS THIRD PLASMA COLLECTION CENTER

BRIEF-Adma Biologics prices follow-on offering of 17.0 mln shares

* Adma Biologics Inc - pricing of offering of approximately 17.0 million shares of its common stock at price of $2.15 per share Source text for Eikon: Further company coverage:

BRIEF-ADMA Biologics now sees offering of 13.6 mln shares of common stock - SEC filing

* Now sees offering of 13.6 million shares of its common stock, up from previous filing of 10.2 million shares - SEC filing Source text: (http://bit.ly/2zmNV1L) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-ADMA Biologics Q3 loss per share $0.59

* ADMA Biologics provides corporate update and reports third quarter 2017 financial results

BRIEF-ADMA Biologics says ‍loss per share was $0.59 for fiscal quarter ended Sept 30​

* ADMA Biologics Inc says for fiscal quarter ended September 30, loss per share was $0.59 - SEC filing

BRIEF-Adma Biologics Inc files for offering of up to $28.75 million of common stock

* Adma Biologics Inc files for offering of up to $28.75 million of common stock Source text: (http://bit.ly/2gvC2f8) Further company coverage:

BRIEF-ADMA Biologics ‍enters into credit agreement for up to $40 mln with affiliated entities of Marathon Asset Management​

* ADMA Biologics Inc - entered into a credit agreement for up to $40 million with affiliated entities of marathon asset management

BRIEF-ADMA Biologics Q2 loss per share $0.55

* ADMA Biologics provides corporate update and reports second quarter 2017 financial results

BRIEF-U.S. Patent and Trademark Office issues immunotehrapy patent to Adma Biologics

* Adma Biologics - U.S. Patent and trademark office has issued to co U.S. Patent no. 9,714,283 which encompasses methods of providing immunotherapy to patients

BRIEF-ADMA Biologics provides corporate timeline and activities update

* ADMA Biologics provides corporate timeline and activities update to stockholders

BRIEF-ADMA Biologics Inc files for resale of 6.04 million shares of co's common stock

* ADMA Biologics Inc files for resale of 6.04 million shares of co's common stock by the selling shareholders Source text: (http://bit.ly/2twQ4Bo) Further company coverage:

BRIEF-Biotest ‍sells US therapy business to Adma Biologics, Inc.​

* RECEIVES ALSO DISTRIBUTION RIGHTS OF SPECIFIED CURRENT PRODUCT AND A RIGHT OF FIRST OFFER FOR DISTRIBUTION OF FUTURE PRODUCTS OF ADMA FOR EUROPE, NEAR AND MIDDLE EAST AND SELECTED ASIAN COUNTRIES

BRIEF-ADMA Biologics Q1 loss per share $0.51

* ADMA Biologics provides corporate update and reports first quarter 2017 financial results

BRIEF-ADMA Biologics to acquire certain assets from Biotest Pharmaceuticals Corp

* ADMA Biologics to acquire certain assets from Biotest Pharmaceuticals Corporation and become a vertically integrated commercial plasma products company

BRIEF-Biotest to sell US therapy business to ADMA Biologics Inc.

* Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up